Biphosphonate-related osteonecrosis of the jaw in an old patient with oral bisphosphonate exposure
DOI:
https://doi.org/10.5712/rbmfc10(36)748Keywords:
Osteoporosis, Postmenopausal, Bisphosphonates, Osteonecrosis, Mandible, PolypharmacyAbstract
Polypharmacy is defined as consumption of five or more concomitant drugs over a period of time, and its incidence is more common in people aged over 65 years. Osteoporosis is the most frequent metabolic bone disease in Western countries and the second most frequent health problem worldwide after cardiovascular diseases. Its main complication is fracture caused by bone fragility, and it affects more women than men. Various treatments are available to prevent them, and one of the most commonly used treatments is bisphosphonate therapy. These drugs are widely used as first-line therapy, especially in postmenopausal osteoporosis. Although biphosphonates are generally well tolerated, they are not free of side effects, and one of the most serious ones is osteonecrosis of the jaw, as shown in the following clinical case. For these and other reasons, it is always important to perform risk-benefit analysis individually before starting any treatment, especially in patients with polypharmacy.
Downloads
Metrics
References
Villafaina Barroso A, Gavilán Moral E. Pacientes polimedicados frágiles, un reto para el sistema sanitário. Inf Ter Sist Nac Salud. 2011;35(4):114-23.
Molina López T, Caraballo Camacho Mde L, Palma Morgado D, López Rubio S, Domínguez Camacho JC, Morales Serna JC. Prevalencia de polimedicación y riesgo vascular en la población mayor de 65 años. Aten Prim. 2012;44(4):216-22. DOI: http://dx.doi.org/10.1016/j.aprim.2011.03.010
Carreño José V, Gayo Loredo ML, Pérez Manzano F, Gómez Ortega AI, Acosta Ferrer M. Interacciones farmacológicas en población polimedicada. Aten Primaria. 2008;40(11):582-3. DOI: http://dx.doi.org/10.1157/13128576
Steinman MA, Landefeld CS, Rosenthal GE, Berthenthal D, Sen S, Kaboli PJ. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc. 2006;54(10):1516-23 DOI: http://dx.doi.org/10.1111/j.1532-5415.2006.00889.x
Brozoski MA, Traina AA, Deboni MC, Marques MM, Naclério-Homem Mda G. Bisphosphonate-related osteonecrosis of the jaw. Rev Bras Reumatol. 2012;52(2):265-70. DOI: http://dx.doi.org/10.1590/S0482-50042012000200010
González López-Valcárcel B, Sosa Henríquez M. Estimación del riesgo de fractura osteoporótica a los 10 años para la población española. Med Clin (Barc). 2013;140(3):104-9. DOI: http://dx.doi.org/10.1016/j.medcli.2011.11.030
Osteoporosis fragility fracture risk: Guideline consultation. NICE Guidance; 2012. Disponível em: http://guidance.nice.org.uk
Moro-Alvarez MJ, Díaz-Curiel M. Diagnóstico y tratamiento de la osteoporosis en mayores de 75 años. Rev Esp Geriatr Gerontol. 2010;45(3):141-9. DOI: http://dx.doi.org/10.1016/j.regg.2009.11.003
Guerra-García MM, Rodríguez-Fernández JB, Puga-Sarmiento E, Charle-Crespo MÁ, Gomes-Carvalho CS, Prejigueiro-Santás A. Incidencia de la fractura de cadera osteoporótica en Galicia en relación con la dispensación de medicamentos con indicación en su prevención y tratamiento. Aten Primaria. 2011;43(2):82-8. DOI: http://dx.doi.org/10.1016/j.aprim.2010.04.010
Brandão CMR, Machado GPM, Acurcio FA. Análise farmacoeconômica das estratégias de tratamento da osteoporose em mulheres na pós-menopausa: uma revisão sistemática. Rev Bras Reumatol. 2012;52(6):912-37. DOI: http://dx.doi.org/10.1590/S0482-50042012000600010
Wells G, Cranney A, Peterson J, Boucher M, Shea B, Welch V, et al. Alendronato para la prevención primaria y secundaria de las fracturas osteoporáticas en mujeres posmenopáusicas (revisión Cochrane traducida) [Internet]. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD001155 [Acesso 14 Ago 2015]. Disponível em: http://www.cochrane.org/es/CD001155/alendronato-para-la-prevencion-primaria-y-secundaria-de-las-fracturas-osteoporoticas-en-mujeres-posmenopausicas.
Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol. 2010;136(8):1117-24. DOI: http://dx.doi.org/10.1007/s00432-010-0907-7
González-Macías J, Guañabens G, Gómez Alonso C, Del Río Barquero L, Muñoz Torres M, Delgado M, et al. Guía de práctiva clínica en la osteoporosis postmenopáusica, glucocorticoidea y del varón. Sociedad Española de Investigación Ósea y del metabolismo Mineral. Rev Clin Esp. 2008;208(Supl 1):1-24.
Areas 1, 2, 3, 5 y 7 de Atencion Primaria. Servicio Madrileno de Salud. Prevencion y tratamiento de la osteoporosis posmenopausica: prevencion de fracturas. Notas Farmacoterapeuticas. 2005;12(5):9-16.
Dirección General de Farmacia y Productos Sanitarios. Recomendaciones para la valoración y tratamiento de la osteoporosis primaria en mujeres de la Comunidad de Madrid. Consejería de Sanidad; 2007.
Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, et al. ; Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010;182(17):1864-73. DOI: http://dx.doi.org/10.1503/cmaj.100771
Vicente Molinero A, Lou Arnal S, Medina Orgaz E, Muñoz Jacobo S, Antonio Ibáñez Estrella J. Osteoporosis treatment with biphosphonates: Approaches to care reality. Aten Primaria. 2011;43(2):95-9. PMID: 20541844 DOI: http://dx.doi.org/10.1016/j.aprim.2010.04.008
Fernandez Avila DG, Mora C, Reyes Sanmiguel E, Londoño JD, Santos Moreno P, Valle-Oñate R. Tratamiento farmacologico de la osteoporosis postmenopáusica. Rev Colomb. Reumatol. 2010;17(2):96-110
Arroyo Pineda V, Tofino Gonzalez I, de la Hija Díaz MB. Ibandronato Mensal para la Osteoporosis. Hoja de Evaluación de medicamentos de Castilla La Mancha. Sescam. 2008;9(7).
Arranz Caso JA, Flores Ballester E, Ngo Pombe S, López Pizarro V, Dominguez-Mompello JL, Restoy Lozano A. Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces. Med Clin (Barc). 2012;139(15):676-80. DOI: http://dx.doi.org/10.1016/j.medcli.2012.05.039
Junquera LM. Comisión científica de la SECOM: Acero J, Burgueño M, de Vicente JC, Martín-Granizo R, Santamaría J, Infante P, et al. Diagnóstico, prevención y tratamiento de la osteonecrosis de los maxilares por bifosfonatos. Recomendaciones de la Sociedad Española de Cirugía Oral y Maxilofacial (SECOM) 2009.
Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65(3):415-23. PMID: 17307586 DOI: http://dx.doi.org/10.1016/j.joms.2006.10.061
Downloads
Published
How to Cite
Issue
Section
License
By submitting a manuscript to the RBMFC, authors retain ownership of the copyright in the article, and authorize RBMFC to publish that manuscript under the Creative Commons Attribution 4.0 license and identify itself as the vehicle of its original publication.